BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lückerath K, Lapa C, Albert C, Herrmann K, Jörg G, Samnick S, Einsele H, Knop S, Buck AK. 11C-Methionine-PET: a novel and sensitive tool for monitoring of early response to treatment in multiple myeloma. Oncotarget 2015;6:8418-29. [PMID: 25762625 DOI: 10.18632/oncotarget.3053] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Hovhannisyan N, Dhilly M, Fidalgo M, Fillesoye F, Guillouet S, Sola B, Barré L. [18F]Fludarabine-PET in a murine model of multiple myeloma. PLoS One 2017;12:e0177125. [PMID: 28472196 DOI: 10.1371/journal.pone.0177125] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
2 Challapalli A, Aboagye EO. Positron Emission Tomography Imaging of Tumor Cell Metabolism and Application to Therapy Response Monitoring. Front Oncol 2016;6:44. [PMID: 26973812 DOI: 10.3389/fonc.2016.00044] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
3 Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, Hillengass J, Engelhardt M, Usmani SZ, Vesole DH, San-miguel J, Kumar SK, Richardson PG, Mikhael JR, da Costa FL, Dimopoulos M, Zingaretti C, Abildgaard N, Goldschmidt H, Orlowski RZ, Chng WJ, Einsele H, Lonial S, Barlogie B, Anderson KC, Rajkumar SV, Durie BGM, Zamagni E. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. The Lancet Oncology 2017;18:e206-17. [DOI: 10.1016/s1470-2045(17)30189-4] [Reference Citation Analysis]
4 Wang L, Hu B, Pan K, Chang J, Zhao X, Chen L, Lin H, Wang J, Zhou G, Xu W, Yuan J. SYVN1-MTR4-MAT2A Signaling Axis Regulates Methionine Metabolism in Glioma Cells. Front Cell Dev Biol 2021;9:633259. [PMID: 33859984 DOI: 10.3389/fcell.2021.633259] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Kircher M, Lapa C. Infection and Inflammation Imaging: Beyond FDG. PET Clin 2020;15:215-29. [PMID: 32145892 DOI: 10.1016/j.cpet.2019.11.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Lapa C, Schreder M, Schirbel A, Samnick S, Kortüm KM, Herrmann K, Kropf S, Einsele H, Buck AK, Wester HJ, Knop S, Lückerath K. [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [18F]FDG and laboratory values. Theranostics 2017;7:205-12. [PMID: 28042328 DOI: 10.7150/thno.16576] [Cited by in Crossref: 67] [Cited by in F6Publishing: 67] [Article Influence: 13.4] [Reference Citation Analysis]
7 Fecher D, Hofmann E, Buck A, Bundschuh R, Nietzer S, Dandekar G, Walles T, Walles H, Lückerath K, Steinke M. Human Organotypic Lung Tumor Models: Suitable For Preclinical 18F-FDG PET-Imaging. PLoS One 2016;11:e0160282. [PMID: 27501455 DOI: 10.1371/journal.pone.0160282] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
8 Kircher S, Stolzenburg A, Kortüm KM, Kircher M, Da Via M, Samnick S, Buck AK, Einsele H, Rosenwald A, Lapa C. Hexokinase-2 Expression in 11 C-Methionine–Positive, 18 F-FDG–Negative Multiple Myeloma. J Nucl Med 2019;60:348-52. [DOI: 10.2967/jnumed.118.217539] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
9 Clark PM, Ebiana VA, Gosa L, Cloughesy TF, Nathanson DA. Harnessing Preclinical Molecular Imaging to Inform Advances in Personalized Cancer Medicine. J Nucl Med 2017;58:689-96. [PMID: 28385796 DOI: 10.2967/jnumed.116.181693] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
10 Lapa C, Kircher M, Da Via M, Schreder M, Rasche L, Kortüm KM, Einsele H, Buck AK, Hänscheid H, Samnick S. Comparison of 11C-Choline and 11C-Methionine PET/CT in Multiple Myeloma. Clin Nucl Med 2019;44:620-4. [PMID: 31274607 DOI: 10.1097/RLU.0000000000002638] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
11 Czyż J, Małkowski B, Jurczyszyn A, Grząśko N, Łopatto R, Olejniczak M, Czyż A, Jachalska A. 18F-fluoro-ethyl-tyrosine (18F-FET) PET/CT as a potential new diagnostic tool in multiple myeloma: a preliminary study. Contemp Oncol (Pozn) 2019;23:23-31. [PMID: 31061633 DOI: 10.5114/wo.2019.83342] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Ferrarazzo G, Chiola S, Capitanio S, Donegani MI, Miceli A, Raffa S, Tagliafico AS, Morbelli S, Bauckneht M. Positron Emission Tomography (PET) Imaging of Multiple Myeloma in a Post-Treatment Setting. Diagnostics (Basel) 2021;11:230. [PMID: 33546455 DOI: 10.3390/diagnostics11020230] [Reference Citation Analysis]
13 Lapa C, Schirbel A, Samnick S, Lückerath K, Kortüm KM, Knop S, Wester HJ, Buck AK, Schreder M. The gross picture: intraindividual tumour heterogeneity in a patient with nonsecretory multiple myeloma. Eur J Nucl Med Mol Imaging 2017;44:1097-8. [PMID: 28238021 DOI: 10.1007/s00259-017-3656-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
14 Mesguich C, Zanotti-Fregonara P, Hindié E. New Perspectives Offered by Nuclear Medicine for the Imaging and Therapy of Multiple Myeloma. Theranostics 2016;6:287-90. [PMID: 26877786 DOI: 10.7150/thno.14400] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
15 Maya Y, Werner RA, Schütz C, Wakabayashi H, Samnick S, Lapa C, Zechmeister C, Jahns R, Jahns V, Higuchi T. 11C-Methionine PET of Myocardial Inflammation in a Rat Model of Experimental Autoimmune Myocarditis. J Nucl Med 2016;57:1985-90. [PMID: 27390159 DOI: 10.2967/jnumed.116.174045] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
16 Lapa C, Garcia-Velloso MJ, Lückerath K, Samnick S, Schreder M, Otero PR, Schmid JS, Herrmann K, Knop S, Buck AK, Einsele H, San-Miguel J, Kortüm KM. 11C-Methionine-PET in Multiple Myeloma: A Combined Study from Two Different Institutions. Theranostics 2017;7:2956-64. [PMID: 28824728 DOI: 10.7150/thno.20491] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
17 Sanderson SM, Gao X, Dai Z, Locasale JW. Methionine metabolism in health and cancer: a nexus of diet and precision medicine. Nat Rev Cancer 2019;19:625-37. [PMID: 31515518 DOI: 10.1038/s41568-019-0187-8] [Cited by in Crossref: 90] [Cited by in F6Publishing: 78] [Article Influence: 30.0] [Reference Citation Analysis]
18 Lapa C, Schreder M, Lückerath K, Samnick S, Rudelius M, Buck AK, Kortüm KM, Einsele H, Rosenwald A, Knop S. [ 11 C]Methionine emerges as a new biomarker for tracking active myeloma lesions. Br J Haematol 2018;181:701-3. [DOI: 10.1111/bjh.14696] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
19 Uehara T, Watanabe M, Suzuki H, Furusawa Y, Arano Y. Amino acid transport system - A substrate predicts the therapeutic effects of particle radiotherapy. PLoS One 2017;12:e0173096. [PMID: 28245294 DOI: 10.1371/journal.pone.0173096] [Reference Citation Analysis]
20 Lapa C, Knop S, Schreder M, Rudelius M, Knott M, Jörg G, Samnick S, Herrmann K, Buck AK, Einsele H, Lückerath K. 11C-Methionine-PET in Multiple Myeloma: Correlation with Clinical Parameters and Bone Marrow Involvement. Theranostics 2016;6:254-61. [PMID: 26877783 DOI: 10.7150/thno.13921] [Cited by in Crossref: 55] [Cited by in F6Publishing: 42] [Article Influence: 9.2] [Reference Citation Analysis]
21 Mayerhoefer ME, Haug A. [Hemato-oncological imaging : Importance of hybrid procedures]. Radiologe 2016;56:597-604. [PMID: 27335021 DOI: 10.1007/s00117-016-0126-6] [Reference Citation Analysis]
22 Bose S, Allen AE, Locasale JW. The Molecular Link from Diet to Cancer Cell Metabolism. Mol Cell 2020;78:1034-44. [PMID: 32504556 DOI: 10.1016/j.molcel.2020.05.018] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
23 Di Giuliano F, Picchi E, Muto M, Calcagni A, Ferrazzoli V, Da Ros V, Minosse S, Chiaravalloti A, Garaci F, Floris R, Muto M. Radiological imaging in multiple myeloma: review of the state-of-the-art. Neuroradiology 2020;62:905-23. [DOI: 10.1007/s00234-020-02417-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
24 Caldarella C, Annunziata S, Pagano L, De Stefano V, Rufini V. Improved Detection of Minimal Residual Disease by 11C-Methionine PET/CT in a Young Patient With Unusual Extramedullary Presentation of Recurrent Multiple Myeloma. Clin Nucl Med 2017;42:e130-4. [PMID: 27922862 DOI: 10.1097/RLU.0000000000001462] [Cited by in Crossref: 4] [Article Influence: 0.7] [Reference Citation Analysis]
25 Iking J, Staniszewska M, Kessler L, Klose JM, Lückerath K, Fendler WP, Herrmann K, Rischpler C. Imaging Inflammation with Positron Emission Tomography. Biomedicines 2021;9:212. [PMID: 33669804 DOI: 10.3390/biomedicines9020212] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Ferreira LM, Li AM, Serafim TL, Sobral MC, Alpoim MC, Urbano AM. Intermediary metabolism: An intricate network at the crossroads of cell fate and function. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2020;1866:165887. [DOI: 10.1016/j.bbadis.2020.165887] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
27 Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, Hillengass J, Engelhardt M, Usmani SZ, Vesole DH, San-Miguel J, Kumar SK, Richardson PG, Mikhael JR, da Costa FL, Dimopoulos MA, Zingaretti C, Abildgaard N, Goldschmidt H, Orlowski RZ, Chng WJ, Einsele H, Lonial S, Barlogie B, Anderson KC, Rajkumar SV, Durie BGM, Zamagni E. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol 2017;18:e206-17. [PMID: 28368259 DOI: 10.1016/S1470-2045(17)30189-4] [Cited by in Crossref: 202] [Cited by in F6Publishing: 110] [Article Influence: 40.4] [Reference Citation Analysis]